Management of Lupus Nephritis Class 3 Plus 5

Initial Immunosuppressive Therapy

The KDIGO guidelines recommend treating lupus nephritis class 3 plus 5 with glucocorticoids plus mycophenolic acid analogs (MPAA) as first-line therapy, following the same treatment algorithm as pure class III/IV disease, since the proliferative component drives management decisions 1, 2
The American College of Nephrology, as per KDIGO guidelines, suggests four equally recommended first-line treatment options: mycophenolic acid analogs (MPAA), low-dose intravenous cyclophosphamide, belimumab + MPAA or cyclophosphamide, and MPAA + calcineurin inhibitor (CNI) 1, 2

The KDIGO guidelines recommend using a reduced-dose glucocorticoid protocol to minimize toxicity while maintaining efficacy, with an initial pulse therapy of methylprednisolone 250-500 mg IV daily for up to 3 days, followed by an oral prednisone taper 1, 2, 3

The KDIGO guidelines suggest that hydroxychloroquine is mandatory for all patients to reduce flares and improve long-term outcomes, and an ACE inhibitor or ARB is required for proteinuria control and blood pressure management 3

The CNI-based regimen (MPAA + CNI) deserves strong consideration in class 3+5 disease, especially for preserved kidney function (eGFR >45) with heavy proteinuria, as it directly addresses podocyte dysfunction 4, 5

After 6 months of induction, the KDIGO guidelines recommend switching to MPAA maintenance, continuing for ≥36 months total, and tapering glucocorticoids to the lowest possible dose 4, 5

The KDIGO guidelines suggest intensive early monitoring every 2-4 weeks for the first 2-4 months, including serum creatinine and eGFR, urine protein-to-creatinine ratio, urinalysis with microscopy, complement levels, anti-dsDNA antibodies, complete blood count, blood pressure, and weight 3, 5
The response definitions, as per KDIGO guidelines, include complete response (proteinuria <0.5 g/g, stable/improved kidney function), partial response (≥50% reduction in proteinuria to <3 g/g, stable/improved kidney function), and no response (failure to achieve partial or complete response) 4, 5